When to Refer Valvular Heart Disease in Africa: The Four T's

The right time to refer valvular heart disease is while the valve can still be repaired, opened or replaced and the heart muscle can still recover, not once the patient is in decompensated heart failure. Dr. Biswarup Purkayastha frames the response as four T's: train the doctors, time the referral, treat the patient with the tools at hand, and use telemedicine to close the gap.

Dr. Biswarup Purkayastha, Consultant – Heart & Lung Transplant and Vascular Surgery, Artemis Hospitals, Gurugram, India, built his masterclass on valvular heart disease in emerging countries around that framework. His argument is practical and financial as much as clinical. A delayed referral does not simply worsen the outlook; it converts a manageable, affordable problem into one that may need a mechanical heart pump or a transplant, at many times the cost.

This article covers the cost of late referral, what can be done in the community before referral, the interventions available, and the case for capacity building over surgical camps. The complete guide to valvular heart disease in emerging countries explains the burden, and the article on echocardiogram reports and referral packages covers what to send with the patient.

When to refer valvular heart disease

Refer early, and do not hesitate. Dr. Purkayastha urged doctors not to be afraid of timing a referral, nor to believe that referring a patient reflects poorly on them or means the patient must leave the country. A referral is a request for a specialist's view; much of the treatment can continue locally.

The clinical reason for early referral is the natural history of rheumatic valve disease. It progresses silently for years. Regurgitant lesions in particular are often left alone on the assumption that they progress slowly, and patients then present with structural damage and heart failure that could have been prevented had they reached a clinic 10 or 15 years earlier. By the time breathlessness, swelling and high diuretic requirements appear, the window for a simple intervention may already have closed.

International guidelines recommend specialist heart team evaluation for patients with severe valve disease or symptoms attributable to it, and specialist review for women with significant valve disease who are pregnant or planning a pregnancy. Dr. Purkayastha's message is that the earlier the conversation, the more options remain.

The cost of a late referral

Dr. Purkayastha put the economics plainly: what today would be a US$10,000 problem might tomorrow require a left or right ventricular assist device (LVAD or RVAD, an implanted pump that takes over the work of a failing ventricle) and become a quarter-million-dollar problem.

Two cases from his practice illustrate the point.

A rapid rise that nobody caught. His team was treating a child referred from abroad with near end-stage heart and lung failure, awaiting a combined heart-lung transplant. Reports from a couple of months earlier recorded a pulmonary artery pressure of about 60 to 63 mmHg. At presentation, his team measured 130 mmHg against a systemic systolic pressure of 100 mmHg. In two to three months, after an acute illness, the lung pressures had risen from below the body's own blood pressure to above it, and nobody had picked it up.

A referral five years too late. On the day of the masterclass, Dr. Purkayastha had written an estimate of about a quarter of a million dollars simply to begin treating a young patient in complete heart-lung failure. Referred perhaps five years earlier, she would have needed a straightforward lung transplant as a child and could have gone on to live a couple of decades of normal life. She had not been neglected: she had been seen by doctors and specialists throughout, and had undergone multiple echocardiograms. The reports were simply irrelevant to the decisions that mattered.

His comparison with evacuation is just as stark. In the week before the masterclass, his team had tried to arrange the medical evacuation of a boy, at a cost of about US$165,000. The real answer, he said, would have been for someone to train ten local cardiologists in that country a couple of years earlier to manage a very simple problem in a very simple way.

Treating valvular heart disease before referral

Much of valvular heart disease care can and should happen locally. Dr. Purkayastha's instruction is to treat the patient with whatever tools are at hand, and he notes that some doctors in Africa already manage follow-up and medical treatment well.

Clinical follow-up and imaging. Patients need regular review, periodic imaging, and risk stratification into subgroups that sets the type and timing of follow-up.

Penicillin prophylaxis. Penicillin is a globally accessible medicine. Patients who have had rheumatic fever or have rheumatic heart disease need long-term secondary prophylaxis to prevent further attacks of rheumatic fever that would damage the valves further. This is usually given as an intramuscular injection of benzathine penicillin G every three to four weeks.

Dental hygiene and education. Dr. Purkayastha includes a good dental hygiene programme in medical management, to prevent dental caries and oral infection, alongside education so that patients understand rheumatic heart disease and what they must do.

Anti-failure medication and diuretics. A little diuretic and appropriate heart failure medication can improve how the heart functions for the time being. Dr. Purkayastha gave an example of the advice he at times sends back to a referring doctor: put the patient on the diuretic furosemide 20 mg twice a day, see how he does over a month, then repeat the echocardiogram or a chest X-ray.

Basic investigations first. He trained under one of India's first female cardiac surgeons, of the early 1970s generation, who taught her trainees to identify and treat heart disease with the bare minimum of investigation. He still asks referring doctors simple questions: why not a chest X-ray, why not a repeat blood work-up? He warned against the opposite habit, increasingly fuelled by internet searches and artificial intelligence tools: starting expensive new therapies without basic diligence, such as putting patients on pulmonary vasodilators (drugs that relax the blood vessels of the lungs) without first trying diuretics.

Valve disease interventions: from valvotomy to transplant

When medical therapy reaches its limit, the options escalate:

1. Closed mitral valvotomy, a surgical procedure in which the fused leaflets of a narrowed mitral valve are separated through the beating heart, without a heart-lung machine.
2. Balloon mitral valvotomy, in which a balloon catheter passed through a vein and across the wall between the upper chambers is inflated inside the narrowed mitral valve to split it open.
3. Valve surgery, repairing or replacing the damaged valve.
4. Transcatheter therapies, which replace or repair valves through a catheter rather than open surgery.
5. Mechanical circulatory support, LVAD and transplantation for patients whose heart failure has become advanced.

Dr. Purkayastha describes the valvotomies as very basic interventions that can still buy a reasonable amount of time once medical therapy has come to an end, keeping valve disease controlled for longer without heart failure. On transcatheter therapy, he admits a change of mind: he once regarded catheter treatments sceptically, but now considers some of them genuinely good bailout options for valve disease. Indicative costs for valve replacement are on the aortic valve replacement cost page. For the surgical side in depth, see the separate masterclasses on mechanical versus tissue heart valves and TAVI versus surgical valve replacement.

The four T's in practice

Train the doctors

Training is the first T. In Dr. Purkayastha's view, referrals will stay haphazard until there is trained manpower on the ground. He proposes that African doctors come for observerships, operate alongside his team and learn what it takes to manage these patients well. In the other direction, he would do perhaps two camps a year with only a couple of operations, spending a couple of weeks purely on training rather than on surgical numbers.

He described what that training would cover: the ABCDs of seeing a patient with valvular heart disease, the ABCDs of reporting it, how to follow patients up in the community and what the relevant paperwork should look like. He offered to travel economy and spend about two weeks training a group of doctors in a single specialty clinic.

Time the referral

Timely referral means the patient arrives while something can still be done, not when the team can only wait. It depends on the training above and on the referral package described in the echo reports article.

Treat the patient

Treatment starts locally, with penicillin, anti-failure medication and diuretics, as set out above.

Telemedicine

Where those measures do not fit together, telemedicine is the way forward. Dr. Purkayastha tends to write detailed replies to queries so that the treating physician understands his reasoning, and offered to dedicate some of his time to weekly or fortnightly consultations. The aim is to guide the local doctor on how to manage and stabilise the patient and, where needed, how to transfer the patient safely. The question raised after the session on how doctors can arrange such consultations is on the Live Discussion page.

Why surgical camps and medical evacuation are not the answer

Dr. Purkayastha speaks from personal experience: flying surgeons into Africa for operating camps has been tried for some 30 years by people he knows, and it does not work. Operating on 30 to 50 patients and returning home can be financially rewarding, but saving 30 to 50 lives is no answer when tens of millions of lives are at stake. He contrasted a surgeon travelling business class to do ten operations, which he could do in two days, with the harder work of spending two weeks training local teams. The answer, he concluded, is training, treating and timing.

A panellist from Ethiopia, Dr. Hannibal Kassahun, a physician with considerable exposure to cardiology, described the same problem through the lens of the health system. Rheumatic heart disease is the leading cause of heart failure in his setting and claims ever younger patients. He identified three delays: patients presenting late because of health-seeking behaviour and poor access to facilities; delays in reaching the right physician once in hospital; and patients not being kept on appropriate preventive therapy. Each delay makes later complications costlier and more devastating.

Dr. Purkayastha's broader work on heart failure surgery, from valve repair to LVADs and transplant, is covered in a separate masterclass.